According to the Complaint, Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company that specializes in developing drug treatment therapies for chronic neurologic disorders.

The Complaint alleges that throughout the Class Period, Adamas' public statements were false and materially misleading.

On March 3, 2020, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on May 15. Defendants filed a Motion to Dismiss the amended Complaint on July 14. On October 8, 2021, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiff was given leave to amend the Complaint. Lead Plaintiff filed a second amended Complaint on November 5.

Defendants filed a Motion to Dismiss the second amended Complaint on December 10, 2021. On January 13, 2013, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

The parties entered into a Stipulation and Agreement of Settlement on February 29, 2024. The Court granted preliminary approval of the Settlement on April 2. On September 27, the Court granted final approval of the Settlement, including an award of Attorneys’ Fees and Expenses, and entered Final Judgment.